The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is a chain of interactions between proteins in a cell.
The JAK-STAT signaling pathway transmits information from extracellular chemical signals to the nucleus resulting in DNA transcription and expression of genes involved in immunity, proliferation, differentiation, apoptosis and oncogenesis. This pathway plays a prominent role in mediating signal transduction for many cytokines.
There are three key parts of JAK-STAT signaling pathway: Janus kinases (JAKs), Signal Transducer and Activator of Transcription proteins (STATs), and receptors (which bind the chemical signals). In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors.
Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes.
In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.
Dysregulation of JAK-STAT signaling is associated with various immune disorders. Accumulating evidence has discovered that STAT3 SNPs is associated with Crohn’s disease, psoriasis and ankylosing spondylitis, STAT4 SNPs is associated with rheumatoid arthritis, Crohn’s disease, systemic lupus erythematosus and Sjogren’s syndrome, and STAT6 SNPs is associated with asthma.
Additionally, given the researches implicating JAK-STAT in autoimmune disease and malignancy, it is not surprising that this pathway has become an attractive target for pharmaceuticals. Ruxolitinib, a JAK1 and JAK2 inhibitor with efficacy for the treatment of polycythemia vera and myelofibrosis, was the first FDA approved JAK inhibitor, or Jakinib.
|PDGFRA||PDGFRA Antibody||PDGFRA Protein||PDGFRA cDNA||PDGFRA ELISA Kit|
|PDGFRB||PDGFRB Antibody||PDGFRB Protein||PDGFRB cDNA||PDGFRB ELISA Kit|
|PIAS1||PIAS1 Antibody||PIAS1 Protein||PIAS1 cDNA||PIAS1 ELISA Kit|
|PIAS2||PIAS2 Antibody||PIAS2 Protein||PIAS2 cDNA||PIAS2 ELISA Kit|
|PIAS3||PIAS3 Antibody||PIAS3 Protein||PIAS3 cDNA||PIAS3 ELISA Kit|
|PIAS4||PIAS4 Antibody||PIAS4 Protein||PIAS4 cDNA||PIAS4 ELISA Kit|
|PIK3CA||PIK3CA Antibody||PIK3CA Protein||PIK3CA cDNA||PIK3CA ELISA Kit|
|PIK3CB||PIK3CB Antibody||PIK3CB Protein||PIK3CB cDNA||PIK3CB ELISA Kit|
|PIK3CD||PIK3CD Antibody||PIK3CD Protein||PIK3CD cDNA||PIK3CD ELISA Kit|
|PIK3R1||PIK3R1 Antibody||PIK3R1 Protein||PIK3R1 cDNA||PIK3R1 ELISA Kit|
|PIK3R2||PIK3R2 Antibody||PIK3R2 Protein||PIK3R2 cDNA||PIK3R2 ELISA Kit|
|PIK3R3||PIK3R3 Antibody||PIK3R3 Protein||PIK3R3 cDNA||PIK3R3 ELISA Kit|
|PIM1||PIM1 Antibody||PIM1 Protein||PIM1 cDNA||PIM1 ELISA Kit|
|PRL||PRL Antibody||PRL Protein||PRL cDNA||PRL ELISA Kit|
|PRLR||PRLR Antibody||PRLR Protein||PRLR cDNA||PRLR ELISA Kit|
|PTPN11||PTPN11 Antibody||PTPN11 Protein||PTPN11 cDNA||PTPN11 ELISA Kit|
|PTPN2||PTPN2 Antibody||PTPN2 Protein||PTPN2 cDNA||PTPN2 ELISA Kit|
|PTPN6||PTPN6 Antibody||PTPN6 Protein||PTPN6 cDNA||PTPN6 ELISA Kit|
|RAF1||RAF1 Antibody||RAF1 Protein||RAF1 cDNA||RAF1 ELISA Kit|
|SOCS1||SOCS1 Antibody||SOCS1 Protein||SOCS1 cDNA||SOCS1 ELISA Kit|